NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.361) was uploaded to the NHS England Website on Friday 2, May 2025.
The following changes have been introduced:
Alpelisib in combination with fulvestrant (ALP1)
For treatment of hormone receptor- positive, HER2-negative, locally advanced or metastatic breast cancer in patients previously treated with a CDK4/6 inhibitor and an aromatase inhibitor where the following criteria have been met
Treatment criteria (#9 and 10) updated
Atezolizumab (ATE1)
The first line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin- based chemotherapy and whose tumours have PD-L1 expression of 5% or more where all the following criteria are mett:
Title and Treatment criteria (#2, 7, 10, 11, 15 and 16) updated
Atezolizumab (ATE3)
Atezolizumab for locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy where all the following criteria are met:
Treatment criteria (#2, 8, 11 and 12) updated
Avelumab (AVE4)
Avelumab monotherapy for the maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have just completed and not progressed on 1st line platinum-containing combination chemotherapy where the following criteria have been met
Treatment criteria (#12 and 15) updated
Capivasertib in combination with fulvestrant (CAP1)
Capivasertib in combination with fulvestrant for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in patients previously treated with a CDK4/6 inhibitor and an aromatase inhibitor where the following criteria have been met
Treatment criteria (#3, 9 and 10) updated
Nivolumab with ipilimumab (NIV24)
Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Treatment criteria (#5, 6 and 7) updated
Olaparib (OLAP5)
Olaparib monotherapy as adjuvant treatment of high-risk TRIPLE NEGATIVE early breast cancer treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation where the following criteria have been met
Treatment criterion (#3) updated
Olaparib in combination with hormone therapy (OLAP6)
As adjuvant treatment of high-risk HORMONE RECEPOR POSITIVE HER 2 NEGATIVE early breast cancer treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation where the following criteria have been met
Treatment criterion (#3) updated